Entero Healthcare Solutions Limited has successfully completed the acquisition of a majority equity stake, specifically 51.51%, in Anand Chemiceutics Private Limited. This development follows a prior intimation regarding the transaction, which was originally disclosed on November 12, 2025. The company has fulfilled the disclosure requirements as mandated by Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. All necessary details pertaining to this acquisition were provided in the company's previous communication.
